Senores Pharmaceuticals Ltd., a global research-driven pharmaceutical company, has reported regulated market revenue of INR 244.8 crore in FY25, marking a 69 percent year-on-year (y-o-y) growth. The EBIDTA for regulated market business stood at INR 101.9 crore, with EBITDA margin of 38.4 percent.

For emerging markets, revenue stood at INR 121.2 crore, a growth of 174 percent on a Y-o-Y basis. Emerging Markets EBITDA Margin stood at 7 percent for FY25.

In the regulated markets, the company currently has 22 own commercial products, 61 approved ANDA products, and 51 pipeline products, including 28 Complex Generics (CGT) opportunity products. Additionally, it has 22 CDMO/CMO commercial products and 69 CDMO/CMO pipeline products. In the emerging markets, the company has 285 approved products and 636 products under registration, with a presence in more than 40 countries.

Commenting on the results, Swapnil Shah, Managing Director, Senores Pharmaceuticals Ltd., said, “We are pleased to report a strong performance for FY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our Total Income and Profit before Tax for FY25 have increased by 91 percent and 183 percent respectively on a year-on-year basis, and we are optimistic about sustaining this momentum going forward.”

He further added, “We continued to make steady progress on our stated strategies. During the quarter, we expanded our portfolio in the Regulated Markets through the acquisition of 14 ANDA’s from Dr Reddy’s and 1 ANDA from Breckenridge Pharmaceuticals. A large part of this acquired ANDA basket has considerable government contract opportunities. Further, our CDMO/CMO segment is gaining traction and continues to scale up well. We have launched 1 new product in the CDMO/CMO segment during the quarter and have 69 products in the pipeline.”

According to Shah, the company’s shift in product portfolio and go-to-market strategies in the Emerging Markets business is beginning to give the desired results, which can be seen in the improvement in margin during the quarter. “We have registered 48 new products across the Emerging Markets during Q4FY25, taking the total portfolio to 285 registered products,” he said.

Talking about the uncertainties due to the tariff situation in the United States of America (USA), he said that it will have to be closely monitored. “We believe we are well placed to navigate the same, given our USFDA-approved manufacturing facility in the USA,” he asserted.